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ABSTRACT

The invention provides a composition comprising a plurality
of nanoceria particles, a sufficient amount of at least one
inhibitor of human carbonic anhydrase II associated with said
plurality of nanoceria particles, and a pharmaceutically
acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of
human carbonic anhydrase II comprises 4-carboxybenzene
sulfonamide. The disclosed composition is useful in treatment of glaucoma.
7 Claims, 6 Drawing Sheets
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FUNCTIONALIZED NANOCERIA
COMPOSITION FOR OPHTHALMIC
TREATMENT

occur with larger particles. Nanoparticles and microspheres
of various synthetic polymers such as poly-butylcyanoacrylate, 15 •1 6 poly lactic acid, 1 7 polymethy lmethacry late, 16 and so
forth as well as natural biocompatible polymers like albumin
18 19
•
have been used for ophthalmic drug delivery applications.

RELATED APPLICATION
This application is a division of U.S. application Ser. No.
12/147,759 which was filed on Jun. 27, 2008 now U.S. Pat.
No. 7,959,949, and which claimed priority from U.S. provisional application Ser. No. 60/946,815, filed on Jun. 28, 2007,
and a continuation in part of Ser. No. 11/412,665 filed on Apr.
27, 2006, now U.S. Pat. No. 7,727,559 issued Jun. 1, 2010.

SUMMARY OF THE INVENTION
10

STATEMENT OF GOVERNMENT RIGHTS
15

The investigation leading to this application was supported
at least in part by a grant from the National Science Foundation. The govermnent may, therefore, have some rights in the
invention, as specified by law.
20

FIELD OF THE INVENTION
The present invention relates to the field of nanotechnology
and, more particularly, to nanoceria particles which carry a
medicinal drug.

25

BACKGROUND OF THE INVENTION
Countless individuals suffer from the ocular disease glaucoma. This condition describes a destruction of optic nerve
cells and deterioration of eyesight as a result of increased
intraocular pressure. The pressure is caused in part by a
buildup of carbon dioxide in the eye. An enzyme that aids in
the production of C02 is human carbonic anhydrase II
(hCAII). This Zn2 + containing metalloenzyme (FIG. 1) catalyzes the reversible hydration of carbon dioxide to bicarbonate and is commonly found in living organisims.
Sulfonamide compounds have been shown to selectively
inhibit hCAII even at low concentratons. 1 Therefore, inhibition ofhCAII with sulfonamides constitutes one of the most
physiological approaches for treatment of glaucoma. In 1958
Beasley et al. reported the in vitro binding of 4-carboxybenzene sulfonamide (CBS) to the carbonic anhydrase (CA)
enzymes. 2 Since then, many other hCAII inhibitors based on
this moiety have been reported. 3 - 5 A remarkable increase in
the hCAII inhibition activity was observed for simple aliphatic esters ofCBS. 5 Also, it is now extensively documented
that significant enhancement of CA inhibition can be
achieved through coupling the primary recognition aromatic
sulfonamide motif with secondary binding elements. 3 •5 - 9 The
mechanism for inhibition ofhCAII by CBS involves coordination of the sulfonamide group (as the anion) to the zinc
atom in the active site of hCAII to form a complex in an
exothermic reaction. 6, 10, 11.
In ophthalmic diseases such as glaucoma, treatment with
conventional liquid eye drops is an inefficient mode of
therapy because oflachrymal drainage losses. Because of the
high elimination rate, only a very small amount ofabout 1-3%
of the dosage actually penetrates through the cornea and is
able to reach intraoculartissues. 12 - 14 Nanoparticles provide a
promising potential as drug carriers for ophthalmic applications. The colloidal nanoparticles may be applied in liquid
form just like eye drop solutions. After optimal drug binding
to the nanoparticles, the ocular bioavailability of many drugs
is significantly enhanced in comparison to normal aqueous
eye drop solutions. 12 Also, smaller particles improve patient
comfort during administration as a scratchy feeling tends to
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With the foregoing in mind, in one embodiment, the
present invention advantageously provides a composition
comprising a plurality of nanoceria particles, a sufficient
amount of at least one inhibitor of human carbonic anhydrase
II associated with said plurality of nanoceria particles, and a
pharmaceutically acceptable carrier containing said plurality
of nanoceria particles with associated inhibitor. The at least
one inhibitorofhuman carbonic anhydrase II preferably comprises 4-carboxybenzene sulfonamide. Preferably, the
enzyme inhibitor is effective against human carbonic anhydrase II and the composition is used in treating an eye disease,
particularly glaucoma, by contacting the eye with the composition.
The composition may also further comprise a detectable
tag associated with the plurality of nanoceria particles. The
skilled will recognize that the term "tag" indicates any atom
or molecule which, when associated with the nanoceria,
imparts a property which allows for tracking of the nanoceria
during treatment. Tracking may be by any known method, for
example, fluorescence responsive to ultraviolet light. In
effect, the tag may be a fluorescent tag associated with said
plurality of nanoceria particles and the fluorescent tag is
preferably a fluorescein compound associated with said plurality of nanoceria particles, in particular, carboxyfluorescem.
In this preferred embodiment of the invention, the nanoceria particles are made by a method comprising a reaction
according to Scheme IA, shown in FIG. 3. Moreover, the
nanoceria particles associated with carboxyfluorescein are
made by a method comprising a reaction according to
Scheme 1B in FIG. 3.
Another embodiment of the invention includes a composition comprising a plurality of nanoceria particles, a sufficient
amount of at least one biologically active agent bound to said
plurality of nanoceria particles, and a pharmaceutically
acceptable carrier containing said plurality of nanoceria particles with bound inhibitor. Preferably, the biologically active
agent comprises a medicinal drug and, particularly, an ophthalmically active drug, which could be an enzyme inhibitor.
In particular, the biologically active agent could comprise a
sulfonamide compound, especially one that inhibits human
carbonic anhydrase.
Another preferred embodiment of the invention includes a
method of treating a patient's eye condition. The method
comprises providing a composition containing a plurality of
nanoceria particles associated with a drug and suspended in a
pharmaceutically acceptable carrier, and contacting the
patient's eye with the composition.
In this embodiment, the drug preferably comprises an
enzyme inhibitor and especially an inhibitor of human carbonic anhydrase. The eye condition comprises glaucoma and
drug comprises 4-carboxybenzene sulfonamide. In the
method, contacting the eye may be accomplished in any fashion known to the skilled but, typically would comprise a
procedure selected from instilling, injecting, diffusing and
combinations thereof.
Nevertheless, while this disclosure preferably comprises
nanoceria compositions and treatments directed to eye con-
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ditions and, particularly, to glaucoma, the invention includes
within its scope the concept of associating a drug with the
nanoceria particles as carriers. The range of drugs that can be
employed in the invention is rather broad and includes any
drug or pharmaceutical composition that can be complexed,
associated with or otherwise bound to the nanoceria particles
without significantly adversely affecting the biological activity of the drug.

indicates a mixture containing ingredients that are compatible
when mixed and which may be administered to a patient or
biological system, whether human, animal or in vitro, in order
to treat a condition or disease. A pharmaceutical composition
may cause a degree of toxicity in the patient to whom it is
administered but, typically, it would be given in a dosage form
and/or amount that does not cause substantial harm to the
patient or biological system being treated. Examples of this
dichotomy would include pharmaceutical compositions for
cancer chemotherapy, which are more toxic for cancer cells
than for normal cells but, nevertheless, exert a level of toxicity
on the patient's normal cells during treatment. A pharmaceutical composition may include one or more medicinal drugs,
which may or may not be prescription drugs. Additionally, the
pharmaceutical composition may include carriers, solvents,
adjuvants, emollients, expanders, stabilizers and other components, whether these are considered active or inactive
ingredients. The skilled will readily understand that the exact
makeup of the composition will depend on the intended route
of administration to the patient, for example, a composition
intended for topical application to the skin will necessarily
contain different components than one intended for ophthalmic instillation. Guidance for the skilled in preparing
pharmaceutical compositions may be found in the U.S. Pharmacopeia-National Formulary and other recognized treatises
in the science of pharmacy.
The figures illustrate the invention disclosed, which comprises inhibition of hCAII, a primary target enzyme for the
treatment of glaucoma. Nanoceria, a nontoxic nanoparticle,
was functionalized with hCAII inhibitors and was tested as a
potential ophthalmic drug delivery tool. We have found various applications of cerium oxide nanoparticles in biotechnology. It was found that treatment with nanomolar concentrations of cerium oxide nanoparticles increases cell longevity 20
and protects the cells from damages caused by X-ray radiation21 and reactive oxygen species (ROS). These previous
studies have revealed that nanoceria particles are nontoxic
and exhibit favorable biocompatibility.
Our studies related to use of nanoceria to protect the retina
from oxidative stress caused by reactive oxygen species
showed that the nanoparticles injected in the vitreous showed
efficacy far away in the retina. 22 Moreover, the nanoceria's
uptake in human lung fibroblast cells was shown to be faster
than the physical transport to the cell 23 suggesting that these
particles have favorable diffusive properties. Therefore, a
composition of Ce02 nanoparticles was deemed as potentially very good candidate for serving as transport agent for
the inhibitors. Since carbonic anhydrase n is a cytosolic
enzyme, that is, it is found in cellular cytoplasm, the inhibitorfunctionalized nanoceria were synthesized to allow easy
entry into living cells.
The first step was to choose a molecule that can attach to
the nanoceria and that can inhibit carbonic anhydrase. Carboxybenzene sulfonamide (CBS) (FIG. 2a) was the primary
choice on the basis of the literature data, where it is shown that
these benzenesulfonamides can serve as inhibitors of carbonic anhydrases and can possess favorable carboxyl groups
for attachment. 8024 It was hypothesized that binding these
molecules to the nanoceria would create an effective inhibitor
of carbonic anhydrase that can be transferred into the cytosol.
Additionally, we also decided to attach a tracking compound,
a carboxyfluoresceinmolecule (FIG. 2b ), to visualize the cell
permeation property of the nanoparticles through a confocal
fluorescence microscope.
The attachment of carboxybenzene sulfonamide and carboxyfluorescein molecules to nanoceria was confirmed using
X-ray photoelectron spectroscopy (XPS). The formation of

BRIEF DESCRIPTION OF THE DRAWINGS
Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 is a cartoon diagram showing the structure of human
carbonic anhydrase;
FIG. 2 depicts the molecular structure of (a) carboxybenzene sulfonamide (CBS) and (b) carboxylfluorescein (CBF);
FIG. 3 depicts schemes for synthesis of functionalized
nanoceria; (A) for nanoceria-CBS; and (B) for nanoceriaCBS-CBF, according to embodiments of the present invention;
FIG. 4 shows high-resolution XPS spectra forthe functionalized nanoceria particles at various conjugation steps; (a) 0
Is scan for epichlorohydrin-functionalized nanoceria; (b) 0 Is
scan for the opened epoxide ring of epichlorohydrin; (c) 0 Is
scan for carboxybenzene sulfonamide-functionalized nanoceria; and (d) C Is scan for carboxyfluorescein-functionalized
nanoceria;
FIG. 5 are images from confocal fluorescence microscopy
of (a) bare nanoceria and (b) nanoceria with fluorophores; and
FIG. 6 shows line graphs indicating the rate of hydrolysis
of 4-nitrophenyl acetate by hCAII, determined using absorbance change at 400 nm, as a function of the nanoceria concentration.
DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, or other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
The term "pharmaceutical composition" is used herein as
commonly known by those skilled in the art and generally
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the fluorophore- functionalized nanoparticles was further
established through confocal fluorescence microscopy.
Finally, the derivatized nanoceria were tested as inhibitors of
the recombinant hCAII enzyme. This was accomplished by
observing the effect of nanoparticles on the rate of hCAIIcatalyzed hydrolysis of the substrate 4-nitrophenyl acetate. 26

Confocal Fluorescence Microscopy (CFM).
An Olympus 161 Fluoroview IX 81 confocal fluorescence
microscope was used. Imaging was performed on prepared
slides with nanoceria samples functionalized with carboxyfluorescein. The concentration of nanoceria was optimized to
1 mg/mL of water for imaging. The emission and excitation
wavelengths for carboxyfluorescein were determined to be
520 and 480 nm, respectively.
Ultraviolet-Visible Spectrophotometry (UV-vis).
Cary IE UV-vis spectrophotometer (UV-vis) from Varian
Inc. was used to determine the inhibition potential of the
nanoceria functionalized with the CBS. The enzyme activity
was measured in 25 mM HEPES buffer, pH 7.0 at 25° C.,
containing 10% acetonitrile. The concentration ofhCAII (obtained from Sigma-Aldrich Company) was kept constant at 1
uM for all the experiments. The concentration of the substrate, 4-nitrophenyl acetate (in acetonitrile), was 1 mM for
experiments carried out with varying concentrations of functionalized nanoceria and varied between 1 and 5 mM for the
kinetic parameter determination studies with constant concentration of the functionalized nanoceria at 0.16667 mg/mL.
The initial rates of 4-nitrophenyl acetate hydrolysis by hCAII
were monitored spectrophotometrically, at 400 nm, using the
Cary Win UV Kinetics application. The molar absorption
coefficient, E of 18 400 M- 1 cm- 1 , was used to determine the
concentration of 4-nitrophenolate formed by hydrolysis, as
reported in the literature. 28
The substrate concentration dependent kinetic data in the
absence and presence of functionalized nanoceria inhibitors
was presented in the form of double reciprocal plots and was
analyzed according to the Michaelis-Menten equation to
obtain the Km and V max values. The inhibitor binding constant, K,, for the functionalized-nanoceria inhibitors was
determined according to the following relationship: 29

Experimental Section
Functionalization of Cerium Oxide Nanoparticles
(Scheme 1, FIG. 3).
Reaction of Ce02 Nanoparticles with Epichlorohydrin and
Ammonia.
The 250 mg of cerium oxide nanopowder (obtained from
Sigma-Aldrich Inc.) was suspended in 10 mL of0.1 M NaOH
solution for 5 min. Then, 5 mL of epichlorohydrin was added,
followed by the addition of 0.5 mL of 2 M NaOH. The
suspension was stirred at room temperature for 6-8 h. The
reaction mixture was then centrifuged, and the supernatant
was decanted. The nanoparticles were washed by water followed by centrifugation. This was done until the pH of the
water was approximately 7 .0. The nanoceria powder was then
dried under vacuum. Next, the nanopowder was again suspended in water, 25 mL of30% ammonium hydroxide soluti on was added, and the reaction mixture was stirred for 14 h.
The product was purified by centrifugation, was washed with
water, and was dried under vacuum again.
Reaction with Carboxybenzene sulfonamide and Carboxyfluorescein.
The nanoparticles from the previous step were functionalized with the carboxybenzene sulfonamide and carboxyfluorescein molecules. These molecules (either 200 mg, 1 mmol
of the CBS or carboxyfluorescein) were sissolved in 15 mL of
dimethylformadide (DMF) and 5 mL of dichloromethane.
Three hundred sevent-five microliters (3.5 mM) ofN-methylmorpholine (NMP) was added followed by the addition of
442.5 mg (1 mmol) of the benzotriazol-1-yl-oxy-tris-(dimethylamino) phosphonium hexafluorphosphage (BOP)
reagent. The reaction mixture was stirred for 10 min at room
temperature. The nanoparticles were then added. The mixture
was stirred for approximately 20 hat room temperature. The
reaction was stopped with 1 mL of water, and the mixture was
centrifuged. It was then washed with DMF, water, and
acetone three times each to get rid of the unattached carboxyfluorescein and finally was centrifuged. The nanoparticles
were finally dried under vacuum.
The carboxyfluorescein-functionalized nanoparticles were
taken through the same procedure to attach additional CBS.
This resulted in nanoparticles functionalized with carboxybenzene sulfonamide, as well as particles with both the CBS
and carboxyfluorescein as shown in Scheme 1.
X-ray Photoelectron Spectroscopy (XPS)
The surface functionalization chemistry of the nanoceria
was examined using a 5400 PHI ESCA (XPS) spectrophotometer. The base pressure during the XPS analysis was
approximately 10- 9 Torr, and Mg Ka X-radiation (1253.6
eV) at a power of 200 W was used. The instrument was
calibrated using a standard gold sample with the binding
energy at 84.0±0.1 eV for Au (4f712 ). All the samples were
placed on a carbon tape. Any charging shift produced during
the scanning was subtracted by using a binding energy scale
with the baseline set at 284.6 eV for the C (ls). 27 The XPS
spectra were deconvoluted using PeakFit (version 4) software. The surface concentration of various conjugates was
158 evaluated from the integrated areas of the peaks corresponding to the respective conjugates.
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where, [I] is inhibitor (functionalized nanoceria) concentration; Km and Km, are Michaelis constants in the absence and
presence of the inhibitor, respectively.
Results
The expected functionalization of nanoceria was confirmed by XPS. The attachments of the epichlorohydrin
linker, the inhibitor, and the fluorophore were established by
examining the high-resolution C (ls) andO (ls) XPS spectra.
The attachment of the fluorophore-functionalized nanoparticles was further confirmed by imaging using a confocal
fluorescence microscope.
Functionalization Chemistry Using X-ray Photoelectron
Spectroscopy (XPS).
The carboxybenzene sulfonamide and carboxyfluorescein
were conjugated by first attaching epichlorohydrin to the
surface of nanoceria particles. This is a standard SN2 reaction
where the oxygen atom of the nanoceria essentially replaces
the chlorine atom of the epichlorohydrin. 30 This results in an
oxygen atom that bonds the cerium with the carbon of the
epichlorohydrin as seen in the first reaction of Scheme 1, as
shown in FIG. 3.
In case of nanocrystalline cerium oxide, the 0 (1 s) spectra
contain two peaks corresponding to the mixed valence state of
Ce (Ce 3 + and Ce4 +) present in its crystal lattice. The peak at
530.5 eV corresponds to Ce4 + while the higher binding
energy peak at about 532.20 eV corresponds to Ce 3 + 0 -31 The
two additional peaks present in the spectra given in FIG. 4a
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demonstrate that the expected functionalization occurred.
These peaks include the 0 (ls) line of the epichlorohydrin's
epoxy group at 533.30 eV and the 0-C bond that connects
the main part of the epichlorohydrin molecule to the cerium
oxide at 534.10 eV. 32 The high-resolution 0 (ls) XPS spectra
thus indicate the successful attachment of the epichlorohydrin molecule to cerium oxide nanoparticles. The loading of
epichlorohydrin on the ceria nanoparticles, calculated from
the integrated areas of 0 peaks corresponding to epichlorohydrin to those for Ce 3 + and Ce4 +, was evaluated to be 3.18
mmol/gm ofCe02.
Ammonia was then used to open up the epoxide ring (SN2
reaction) on the epichlorohydrin molecule to form amine
(-NH 2 ) and hydroxyl (-OH) groups available for further
reactions (FIG. 3, Scheme 1). The indication that this reaction
occurred lies in the diminishment of the peak at 533.30 from
FIG. 4a. The new peak at 533.00 eV in FIG. 4b corresponds
to the newly formed-OH groups. 32 However, FIG. 4b also
confirms that the 0---C bond that links the epichlrohydrin
molecule bond to the nanoceria remained with the peak at
534.00 eV. Thus, the epichlrohydrin was still attached to the
nanoceria and the epoxide ring opened as expected. The integrated area analysis of the peaks confirmed almost 100% ring
opening for the epoxide group of the epichlorohydrin conjugated to the cerium oxide nanoparticles.
The nanoceria now possessed two functional groups that
could be further functionalized by the carboxybenze sulfonamide and carboxyfluorescein molecules. Both of them have
carboxyl groups that can react to the available amine and
hydroxyl groups from the opened ring of the surface-functionalized nanoceria (FIG. 2). The coupling reactions
included standard peptide coupling reagents, N-methyl morpholine (NM)) and benzotriazol-1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate (BOP). The
reactions were conducted in dimethylformamide (DMF), a
polar aprotic solvent that facilitates the coupling.
The attachment of the inhibitor, CBS, to the amine group
was confirmed by the 0 ls XPS spectrum in FIG. 4c. The
locations of all of the peaks essentially remained the same
from the previous spectrum in FIG. 4b except for two additional peaks. These peaks at 531.13 and 531.70 eV correspond to the double-bonded oxygen atoms of the C=O and
S=O bonds, respectively, that are part of the CBS. The XPS
analysis thus indicated that the inhibitor bonded to the nanoceria particles. The loading yield determined from the deconvoluted peak areas was evaluated to be 3.14 mmol/gm of
Ce0 2 (98.8%).
Instead of the 0 ls spectrum, the carbon (C ls) spectrum
was used to confirm the attachment of carboxyfluorescein,
because this large molecule shielded many of the oxygen
peaks seen in the previous oxygen spectra. FIG. 4d shows the
various peaks present in the XPS spectra corresponding to the
different C positions in the structure of the carboxyfluorescein functionalized ceria nanoparticles. It confirms that the
fluorophore was also attached successfully to the ceria nanoparticles via epichlorohydrin linkage. The XPS peak analysis
gave the surface concentration of the fluorophore to be 6.0
mmol/gm of Ce0 2 . The results of the high-resolution XPS
spectra for all of the reactions are summarized in Table S 1 of
the Supporting Information (not shown but incorporated
herein by reference; this material is available to the public free
of charge via the Internet at http://pubs.acs.orq a web site of
The American Chemical Society).
Confocal Fluorescence Microscopy.
Further evidence that the fluorescent molecules bonded
was presented in the confocal fluororescence microscopy
images. As seen in FIG. 4, the carboxyfluorescein-function-

alized nanoparticles were clearly visible under a confocal
fluorescence microscope O'-ex=480 nm; "-em =520 nm) as
green dots while the bare nanoceria resulted in images showing a black background. An individual green dot represents a
small agglomerate of the ceria nanoparticles (particle size:
10-20 nm) successfully functionalized with carboxyfluorescein. This further demonstrates that the fluorophores were
attached to the nanoceria. The procedure for attaching these
fluorescent molecules can be used in future studies to track
the nanoceria as they are inserted into living cells. Future
studies will involve inserting these particles in vivo and tracking their movement as they approach the expected locations
of enzymes.
Inhibition Studies.
The final facet of the study involved determining whether
the functionalized nanoceria inhibited the recombinant
hCAII enzyme. This was accomplished by observing the
effect of nanoparticles on the rate of hCAII-catalyzed
hydrolysis of the substrate 4-nitrophenyl acetate. Essentially,
the nanoparticles were mixed with a solution of the 4-nitrophenyl acetate and enzyme. The UV-vis spectrophotometer
then measured the absorbance values at 400 nm as 4-nitrophenylacetate was hydrolyzed to form 4-nitrophenolate. The
change in the absorbance values at different concentrations of
nanoceria indicated the inhibiting effect of the conjugated
nanoparticles.
The declining slopes in FIG. 6 reveal that, when the inhibitor-functionalized nanoceria bound to the active site of
hCAII, the rate of formation of 4-nitrophenolate from 4-nitrophenyl acetate decreased. A decrease in the rate of its
formation produced a solution that became tinted at a slower
rate, which was represented by the decrease in the absorbance
values as a function of time (see FIG. 6). hCAII's activity
declined with increased concentration of nanoceria, as indicated by the decreasing rate for the hydrolysis of 4-nitrophenyl acetate to 4-nitrophenolate. Bare nanoceria did not affect
the rate of hydrolysis of 4-nitrophenyl acetate. When the
inhibitor was paired with the fluorophore, the inhibition was
better than with nanoceria functionalized only with CBS. The
kinetic parameters (Km, V max and K,) for the functionalized
nanoceria samples, determined using the double-reciprocal
plots, are summarized in Table 1.
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Kinetic Parameters of the hCAII-Catalyzed Reaction in the
Absence and Presence ofFunctionalized-Nanoceria Inhibitors
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50 no inhibitor
nanoceria with
inhibitor (CBS)
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nanoceria with
inhibitor (CBS)
and fluorophore
(carboxyfluorescene)

V maxCmM/min) K; (mg/mL)
115.23 ± 1.36
125.40 ± 0.98

3.02 ± 0.15
3.24 ± 0.08

1.89 ± 0.16

135.24 ± 1.10

3.12 ±0.10

0.96 ± 0.09

Discussion
One of the emerging goals of nanotechnology is to functionalize inert and biocompatible materials to impart precise
biological functions. Several hybrid organic/inorganic nanoparticles have been described for diagnostic or therapeutic
use, 34•35 including quantum dots, 36037 polymers, 38 and magnetofluorescent nanoparticles. 39 Although many coupling
systems have been reported for polymeric nanoparticle conjugation with varying degrees of success, 40 •41 the coupling
and functionalization ofinorganic nanoparticles with biomolecules has only been carried out with a limited number of
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chemical methods. Niemeyer42 has written an elaborate
review on usage of various coupling agents such as citrate,
streptavidin, and various other complex linker molecules with
amide and carboxylic acid end groups for coupling of inorganic nanoparticles (Au, Ag, ZnS, CdS, Sn0 2 , Ti0 2 , etc.) and
biomolecules (proteins, DNA, etc.).
In this disclosure, we have shown the simultaneous conjugation of the hCAII inhibitor, CBS, and the fluorophore,
carboxyfluorescein, to cerium oxide nanoparticles via
epichlorohydrin as a linker molecule. Epichlorohydrin is a
highly reactive compound used in manufacture of epoxy and
phenoxy resins. It is also used as a solvent and in the synthesis
of glycerol. Anirudhan et al. 43 have developed a new adsorbent system for phosphate removal from wastewaters using
epichlorohydrin to modify lignocellulosic residue. Also, it
has been used in synthesis of lipopolyhydroxylalkylamines
for gene delivery. 44 Weissleder et al. 45 cross-linked the
monocrystalline magnetic nanoparticles, consisting of 3 nm
core of (Fe2 0 3 )n(Fe3 0 4 )m covered with a layer of dextran,
with epichlorohydrin and aminated them by reaction with
ammonia to provide primary amine groups for the parallel
synthesis of a library comprising 146 nanoparticles decorated
with different synthetic small molecules. Similarly, in the
present study, epichlohydrin was attached to the ceria nanoparticles via a condensation reaction between the organochloride group from epichlorohydrin and the surface
hydroxyl groups of the nanoceria particles and then was aminated to provide primary amine group for conjugation of
enzyme inhibitor as well as the fluorophore to the nanoceria
particles. The epichlorohydrin may have provided a spacer
that allowed the inhibitor to reach the active site of the carbonic anhydrase and to reduce any steric hindrance of the
enzyme's interaction with the inhibitors on the surface of the
nanoparticles. Furthermore, the inhibition was nearly directly
proportional with increased concentration of the functionalized nanoceria inhibitors (FIG. 6). The analysis of the kinetic
data conformed to the competitive type of inhibition model.
Higher Km values in the presence of functionalized nanoceria
inhibitors than in its absence eliminate the possibility of
"noncompetitive inhibition". In conclusion, these results
demonstrate that inhibition of the hCAII enzyme can be
achieved using nanoceria particles surface-functionalized
with CBS.
The aim of the present application is to show that a successful conjugation of the ceria nanoparticles can be carried
out using epichlorohydrin as a linker molecule and that such
conjugated nanoparticles can be used for hCAII inhibition
along with fluorescence-imaging capabilities. The inhibition
results may be further enhanced using multiprong surfacebinding groups. Our earlier studies in this regard have shown
a potential strategy to improve inhibition ofhCAII by attaching a surface-histidine recognition group to the inhibitor. Our

on-going investigations include the usage of the same conjugation process for multiprong inhibitors of hCAII for
improved results.
CONCLUSION
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Nanoceria were successfully functionalized and tested as
inhibitors for hCAII. High-resolution XPS C ls and 0 ls
spectra were effectively utilized to follow the necessary steps
in the reaction process. The fluorescence microscope images
and quantitative observations further confirmed that the carboxyfluorescein molecules bonded to the nanoceria particles.
These results are very promising, and more studies will likely
evolve into an inhibition of hCAII in living cells and an
effective treatment of glaucoma and other diseases.
Furthermore, inhibitors for other disease associated
enzymes can be immobilized on the nanoceria and then
applied to the enzymes. The potential applications for functionalized cerium oxide nanoparticles seem limitless as a
potential nontoxic drug delivery tool.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
That which is claimed is:
1. A method of treating a patient's eye condition, the
method comprising:
providing a composition containing a plurality of nanoceria particles associated with a drug and suspended in a
pharmaceutically acceptable carrier; and
contacting the patient's eye with the composition.
2. The method of claim 1, wherein the drug comprises an
enzyme inhibitor.
3. The method of claim 1, wherein the drug comprises an
inhibitor of human carbonic anhydrase.
4. The method of claim 3, wherein the eye condition comprises glaucoma.
5. The method of claim 1, wherein the drug comprises
4-carboxybenzene sulfonamide.
6. The method of claim 5, wherein the eye condition comprises glaucoma.
7. The method of claim 1, wherein contacting comprises a
procedure selected from instilling, injecting, diffusing and
combinations thereof.
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